These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 14671175

  • 1. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.
    Meriggiola MC, Costantino A, Cerpolini S, Bremner WJ, Huebler D, Morselli-Labate AM, Kirsch B, Bertaccini A, Pelusi C, Pelusi G.
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5818-26. PubMed ID: 14671175
    [Abstract] [Full Text] [Related]

  • 2. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C.
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [Abstract] [Full Text] [Related]

  • 3. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
    Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, Pavani A, Capelli M, Flamigni C.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
    [Abstract] [Full Text] [Related]

  • 4. Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen.
    Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM.
    J Androl; 2002 Aug; 23(5):684-90. PubMed ID: 12185103
    [Abstract] [Full Text] [Related]

  • 5. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.
    McLachlan RI, O'Donnell L, Stanton PG, Balourdos G, Frydenberg M, de Kretser DM, Robertson DM.
    J Clin Endocrinol Metab; 2002 Feb; 87(2):546-56. PubMed ID: 11836283
    [Abstract] [Full Text] [Related]

  • 6. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
    McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):142-9. PubMed ID: 14715841
    [Abstract] [Full Text] [Related]

  • 7. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM, Gow SM, Wu FC.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [Abstract] [Full Text] [Related]

  • 8. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 9. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.
    Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C.
    Fertil Steril; 1997 Nov; 68(5):844-50. PubMed ID: 9389813
    [Abstract] [Full Text] [Related]

  • 12. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [Abstract] [Full Text] [Related]

  • 13. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate.
    Meriggiola MC, Costantino A, Saad F, D'Emidio L, Morselli Labate AM, Bertaccini A, Bremner WJ, Rudolph I, Ernst M, Kirsch B, Martorana G, Pelusi G.
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2005-14. PubMed ID: 15634716
    [Abstract] [Full Text] [Related]

  • 14. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 15. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [Abstract] [Full Text] [Related]

  • 16. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C, Yeung KK.
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [Abstract] [Full Text] [Related]

  • 17. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ.
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [Abstract] [Full Text] [Related]

  • 18. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [Abstract] [Full Text] [Related]

  • 19. Reinitiation of sperm production in gonadotropin-suppressed normal men by administration of follicle-stimulating hormone.
    Matsumoto AM, Karpas AE, Paulsen CA, Bremner WJ.
    J Clin Invest; 1983 Sep; 72(3):1005-15. PubMed ID: 6411766
    [Abstract] [Full Text] [Related]

  • 20. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.